Navigation Links
RRD Selected as Development Partner for NIH Therapeutics for Rare and Neglected Diseases Program
Date:1/24/2011

ROCKVILLE, Md., Jan. 24, 2011 /PRNewswire/ -- RRD International, a strategy-driven biotech and pharmaceutical product development company, announced today that it has entered into a partnership with the National Institutes of Health (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program as a regulatory support and development partner.

The RRD and TRND partnership will focus on two rare disease drug development projects: Hereditary Inclusion Body Myopathy (HIBM), a rare adult-onset neuromuscular disorder and Niemann Pick type C1 Disease (NPC1), a rare neurodegenerative genetic disease.  

"We look forward to combining the product development strengths of RRD with the resources of the NIH TRND program to develop important new treatments for these rare diseases," said Charles (Chuck) Finn, Ph.D., President, CEO, and Co-Founder of RRD International.

As a new congressionally mandated program, TRND is designed to advance preclinical and early clinical development of new drugs for rare and neglected diseases. The program also drives forward adoption of new technologies and treatment paradigms which improve product development efficiency for these diseases.  TRND has formed numerous collaborations with researchers from academia and industry to work on specific rare or neglected diseases.  

"TRND has established partnerships with companies and researchers to identify the most promising molecules that may result in new treatments for rare and neglected diseases," said Christopher P. Austin, M.D., director of the NIH TRND effort. "It is important to note that drug development is not a trivial process and the failure rate for any molecule or compound is high."

The program aims to speed development of new drugs that might otherwise be ignored by industry because they are too early in the development process where the failure rates are high or would not be sufficiently profitable. To make a potential compound attrac
'/>"/>

SOURCE RRD International
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information
2. CSA Medical Selected to Present at Mid-Atlantic Bio Conference
3. PMC BioTec Selected as a GoingGreen Silicon Valley 100 Winner
4. PROLOR Biotechs Longer-Acting Human Growth Hormone Data Selected for Presentation at 5th International Congress Of The Growth Hormone Research Society and IGF Society
5. Honeywell UOP Technology Selected to Support Conversion of Biomass to Fuel at California Renewable Energy Facility
6. Ion Torrent Selected as World Economic Forum Technology Pioneer
7. Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
8. Genedata Phylosopher Selected for ERA-NET sncRNA Project
9. NeoStem Selected to Present at American Society for Apheresis
10. DNA Genoteks Oragene(R) DNA Product Selected by The Anthony Nolan Trust for Pilot Project
11. OrthoAccel Technologies, Inc. Selected to Pitch at the 2010 WBTshowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... discussions with certain shareholders representing approximately 45% of the ... with certain matters including the appointment of auditors at ... 26, 2015 (the "Meeting") it intends to adjourn the ... place when the Meeting reconvenes. The Meeting will be ...
(Date:3/25/2015)... NEW YORK , March 25, 2015 /PRNewswire/ ... has commenced Factual Stock Report coverage on ... Bioceuticals (OTCQX: ATTBF; CSE: ATT): is a specialty ... subsidiaries of cultivating, licensing and marketing proprietary ingredients, ... medicinal markets in North America ...
(Date:3/25/2015)... and REYKJAVIK, Iceland , March 25, 2015 ... the genome to create better medicine, today congratulated the scientists ... of whole-genome data yet undertaken. The studies ... – are built around the most comprehensive population-wide tally ... deCODE scientists led by Kari Stefansson , deCODE,s founder ...
(Date:3/25/2015)... 25, 2015 Data from Evidence ... of Action in Neuromuscular Diseases , South ... Incorporated (Nasdaq: CYTK) announced the publication of a ... activator tirasemtiv in the journal Neurotherapeutics. This ... of Effect” or hypothesis-generating clinical trial which evaluated ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
... University bioengineers have not only figured out a way to ... can now slip them into the command center -- or ... important information or drop off payloads. Using silver nanoparticles ... an uncanny ability to penetrate human cells, the scientists ...
... Wis., Sept. 28 Sheffield Bio-Science, a Kerry ... and marketing alliance with Girus Life Sciences. Under ... Global Sales, Distribution and Development Partner for Girus ... Regocel supplements are small molecule yield enhancers ...
... Sept. 28 Decision Resources, one of the world,s ... issues finds that, owing to increasing generic availability of ... $26 billion in 2009 to $23 billion in 2019 ... Kingdom and Japan. The Pharmacor 2010 findings ...
Cached Biology Technology:Sneaking spies into a cell's nucleus 2Sneaking spies into a cell's nucleus 3Sheffield Bio-Science Adds Chemically Defined Media Supplements to Product Portfolio 2Due to Generic Erosion, the Hypertension Drug Market Will Decline by $3 Billion from 2009 to 2019 2
(Date:3/24/2015)...   NexID Biometrics LLC, whose spoof-mitigation technology ... announced the beginning of shipments of version 2.0 of ... company, based in Potsdam, N.Y. , ... which began here today at the Walter E. Washington ... its SDK boosts the accuracy rate range to 96.5 ...
(Date:3/23/2015)... 2015  In the 2014 fiscal year, irs.gov recorded ... This figure accounts for a fraction of the estimated ... Report, exceeds $11 billion globally. The polygraph has traditionally ... has occurred. Investor Mark Saint Juste along ... Paolella partnered to administer the test in a ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... wallet is one of the products featured in 2015 ... 20th at 11:00 PM EST on the DIY Network. ... Las Vegas , site of the ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... technology that makes it possible to zoom in on ... at Dana-Farber Cancer Institute have identified nearly 100 chromosome ... non-small cell lung cancer. The findings provide new clues ... most common type of lung cancer –?and one of ...
... water quality, creation of coastal "dead zones," the collapse ... some of the potential consequences of humankind's degradation of ... report launched today. , Humans have changed ecosystems more ... in any other period, some 60 per cent of ...
... of molecular signals that instructs cells with fatally damaged DNA ... p53 is inactivated, as it is in over half of ... to operate, and body cells start to accumulate mutations, which ... this vital safeguard has been studied in great detail for ...
Cached Biology News:High-powered gene profiles provide clues to genes involved in common form of lung cancer 2High-powered gene profiles provide clues to genes involved in common form of lung cancer 3UN: World in big ecological mess 2UN: World in big ecological mess 3Cancer related gene p53 not regulated as indicated by previous tissue culture research 2Cancer related gene p53 not regulated as indicated by previous tissue culture research 3
Mouse polyclonal antibody to NR2F2 - nuclear receptor subfamily 2, group F, member 2...
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The 10-user network license entitles ten users to access data f...
Mouse monoclonal antibody raised against a partial recombinant NEK2. NCBI Entrez Gene ID = NEK2...
... imaging controller is a successor of the ... users to comfortably observe, record and utilize ... an 8.4 inch LCD (XGA) monitor and ... cameras including the DS-Fi1 , DS-5Mc , ...
Biology Products: